Kymera Therapeutics, Inc.

11 clinical trials · Sponsor

Record	Firm	Date
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study (NCT07677059)	Kymera Therapeutics, Inc.	2026-07-01
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants (NCT07412288)	Kymera Therapeutics, Inc.	2026-02-23
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma (NCT07323654)	Kymera Therapeutics, Inc.	2026-01-28
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis (NCT07217015)	Kymera Therapeutics, Inc.	2025-11-24
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD) (NCT06945458)	Kymera Therapeutics, Inc.	2025-04-17
First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants (NCT06673667)	Kymera Therapeutics, Inc.	2024-10-22
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors (NCT05775406)	Kymera Therapeutics, Inc.	2023-05-15
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL (NCT05233033)	Kymera Therapeutics, Inc.	2022-06-13
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors (NCT05225584)	Kymera Therapeutics, Inc.	2022-05-19
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) (NCT04772885)	Kymera Therapeutics, Inc.	2021-02-23
Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis (NCT04440410)	Kymera Therapeutics, Inc.	2020-05-28

Track Kymera Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.